Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

Author： Higgs Jenny E Payne Katherine Roberts Chris Newman William G

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.11, Iss.2, 2010-02, pp. : 177-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity

By Reuther Lene Vainer Ben Sonne Jesper Larsen Niels-Erik

European Journal of Clinical Pharmacology, Vol. 59, Iss. 11, 2004-01 ,pp. : 797-801

Springer Publishing Company

Access to resources Recommend Favorite

TPMT genotypes not predictive of thiopurine ADRs

Inpharma, Vol. 1, Iss. 1409, 2003-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 6, Iss. 1, 2008-03 ,pp. : 33-44

Bentham Science Publishers

Access to resources Recommend Favorite

Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs

By Sheffield Leslie J Irving Peter Gupta Arun Byron Keith Macrae Finlay A Phillimore Hazel Dronavalli Mithilesh Rose Rosemary George Peter Walmsley Trevor Dixon Barbara Poole Susan Dooley Michael Sparrow Miles

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1091-1099

Future Medicine

Access to resources Recommend Favorite

Psychotropic medications: increased risk of fracture?

Reactions Weekly, Vol. 1, Iss. 1137, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite